Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Benjamin F. Edwards & Company Inc.

Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVOGet Rating) by 179.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,190 shares of the company’s stock after acquiring an additional 1,406 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in Novo Nordisk A/S were worth $218,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in NVO. Jennison Associates LLC lifted its holdings in shares of Novo Nordisk A/S by 90.3% during the 2nd quarter. Jennison Associates LLC now owns 10,517,221 shares of the company’s stock valued at $1,171,934,000 after acquiring an additional 4,989,744 shares in the last quarter. Folketrygdfondet lifted its holdings in Novo Nordisk A/S by 769.6% in the 2nd quarter. Folketrygdfondet now owns 4,142,878 shares of the company’s stock worth $461,641,000 after buying an additional 3,666,475 shares in the last quarter. BlackRock Inc. lifted its holdings in Novo Nordisk A/S by 45.4% in the 1st quarter. BlackRock Inc. now owns 5,035,879 shares of the company’s stock worth $559,235,000 after buying an additional 1,571,747 shares in the last quarter. WCM Investment Management LLC lifted its holdings in Novo Nordisk A/S by 35.1% in the 2nd quarter. WCM Investment Management LLC now owns 3,850,053 shares of the company’s stock worth $423,814,000 after buying an additional 999,342 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Novo Nordisk A/S in the 2nd quarter worth $69,488,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $136.32 on Friday. Novo Nordisk A/S has a 52 week low of $91.51 and a 52 week high of $139.05. The company has a current ratio of 0.92, a quick ratio of 0.74 and a debt-to-equity ratio of 0.31. The stock has a market cap of $308.49 billion, a price-to-earnings ratio of 40.45, a price-to-earnings-growth ratio of 1.74 and a beta of 0.50. The company has a 50-day moving average price of $126.66 and a two-hundred day moving average price of $113.90.

Novo Nordisk A/S (NYSE:NVOGet Rating) last posted its earnings results on Wednesday, November 2nd. The company reported $0.86 EPS for the quarter, topping the consensus estimate of $0.84 by $0.02. Novo Nordisk A/S had a net margin of 31.57% and a return on equity of 72.57%. The firm had revenue of $6.17 billion during the quarter, compared to analysts’ expectations of $6.09 billion. Analysts forecast that Novo Nordisk A/S will post 3.38 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on NVO. StockNews.com began coverage on shares of Novo Nordisk A/S in a report on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Credit Suisse Group boosted their price objective on shares of Novo Nordisk A/S from 820.00 to 860.00 in a report on Friday, November 4th. Oddo Bhf upgraded shares of Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a report on Thursday, September 29th. Barclays boosted their target price on shares of Novo Nordisk A/S from 825.00 to 850.00 and gave the stock an “overweight” rating in a research report on Friday, October 14th. Finally, Cowen boosted their target price on shares of Novo Nordisk A/S from $130.00 to $145.00 in a research report on Monday, December 12th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and an average price target of $697.78.

Novo Nordisk A/S Company Profile

(Get Rating)

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.

See Also

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVOGet Rating).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.